Fingerstick Test Matches Lab Accuracy for Hepatitis B

Getting tested for hepatitis B just became a whole lot easier for millions of people living far from major medical centers.

Researchers at Australia's Kirby Institute have proven that a fingerstick blood test for hepatitis B is just as accurate as the traditional lab tests that require traveling long distances and waiting weeks for results. Better yet, the new test delivers answers in just 60 minutes.

"The fingerstick point-of-care test is highly accurate, closely matching the accuracy of traditional tests," explains Professor Gail Matthews, who led the research. The findings were published in the Journal of Clinical Microbiology.

This matters because hepatitis B kills over 1 million people every year, yet most people with the disease don't have easy access to testing. The virus attacks the liver and can lead to cirrhosis, liver failure, and cancer if left untreated.

Here's the problem the new test solves: Not everyone with hepatitis B needs treatment, but DNA tests are essential for determining who has high enough virus levels to benefit from medication. Until now, those DNA tests required venous blood samples processed only in centralized laboratories.

That meant patients in remote areas had to travel long distances, make multiple clinic visits, and wait days or weeks for results. Many people simply couldn't access the care they needed.

The fingerstick test changes everything. It can be performed by a broader range of healthcare workers in small clinics, using just a drop of blood from a finger prick. The technology is already being used successfully for other diseases like hepatitis C.

The Ripple Effect

The timing couldn't be better. Of the 254 million people worldwide living with chronic hepatitis B, only 14% have been diagnosed and just 8% are receiving treatment. No country is currently on track to meet the World Health Organization's goal of eliminating hepatitis B as a public health threat by 2030.

The WHO recently updated its guidelines to recommend these point-of-care DNA fingerstick tests globally, and this study provides the scientific evidence to back up that recommendation. Most people with chronic hepatitis B live in low and middle-income countries where access to testing and treatment remains severely limited.

"Access to testing is a major barrier to progress on hepatitis B elimination," says Associate Professor Thomas Tu from Hepatitis B Voices. "We are hopeful that this research will support the roll-out of point-of-care testing for hepatitis B, enhancing access and ultimately, improving health and saving lives."

The technology is ready, the evidence is solid, and lives are waiting to be saved.